Goldenrod Therapeutics, Inc.

Biotechnology · HOUSTON, TX

BiotechnologySEC Form D

Goldenrod Therapeutics, Inc. filed a Form D with the U.S. Securities and Exchange Commission on June 3, 2026, reporting $3,245,355 raised toward a $6,510,000 offering.

Incorporated in Texas and based in HOUSTON, TX, it operates in the Biotechnology sector.

Companies file a Form D within 15 days of the first sale of securities in a private offering under Regulation D — an early, public signal that Goldenrod Therapeutics, Inc. has raised capital from private investors.

Browse more recently funded companies in Biotechnology.

Executives & Directors

  • Leo Linbeck IIIDirector
  • Atul VaradhacharyExecutive Officer · Director
  • Thomas BrenninkmeijerDirector
  • Dev ChatterjeeExecutive Officer
  • Leo Linbeck IVExecutive Officer
  • Mark WorschehExecutive Officer · Director

Recently funded in Biotechnology

Other companies that recently filed a Form D

$10.0MRaised

Human Biotech, Inc.

BiotechnologyCAMBRIDGE, MA
May 22, 2026View SEC Form D
$1.0MRaised

Optimeos Life Sciences, Inc.

BiotechnologyPRINCETON, NJ
May 22, 2026View SEC Form D
$2.5MRaised

BioStem Technologies, Inc.

BiotechnologyPOMPANO BEACH, FL
May 21, 2026View SEC Form D
$1.6MRaised

Biolexis Therapeutics Inc.

BiotechnologyLEHI, UT
May 20, 2026View SEC Form D
$700.0KRaised

ViCardia Therapeutics, Inc.

BiotechnologySAN FRANCISCO, CA
May 19, 2026View SEC Form D
Goldenrod Therapeutics, Inc. raised $3.2M — SEC Form D